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Abstract: Since osteonecrosis of the jaw was related to biphosphonate administration by Marx, 
studies showing clinical symptoms, drug and surgical therapies overwhelmed the literature. 
Furthermore, the literature demonstrated the correlation between chronic biphosphonate 
adsumption and osteonecrosis of the jaw onset. Nitrogen-containing biphosphonates are widely 
used for the management of metastatic cancer, for prevention and treatment of osteoporosis, for 
the treatment of Paget’s disease, and for the management of acute hypercalcemia. According to 
our experience, the treatment of BRON-J’s lesions is difﬁ  cult and prolonged. For this reason, 
in order to avoid these complications it is mandatory to perform a risk staging in patients who 
must undergo biphosphonate administration. When pharmacologic treatments with antibiotics 
and local antiseptics are not able to control the development of BRON-J’s complications, 
the clinicians should perform radical surgical treatments such as the resection of the bone 
involved.
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Introduction
Osteonecrosis of the jaw is a chronic osteomielitis that recognizes a multifactorial 
genesis, connected to both local and systemic factors. The relevant systemic 
factors capable to inﬂ  uence development of osteonecrosis of the jaw encompass 
immunosuppression, chemotherapy, corticosteroid therapy, and endocrine diseases.
Pharmacologic-related osteonecrosis of the jaw (BRON-J) in oncologic patients 
treated with intravenous biphosphonates was an unknown clinical entity until 2003, 
when Marx described 36 cases of BRON-J in patients affected by malignant tumors.1 
Biphosphonates stand as an important group of drugs for the treatment of metabolic and 
oncologic pathologies involving the skeletal system. Biphophonates act by inhibiting 
osteoclastic bone resorption. The most common drugs utilized in the prevention and 
therapy of osteoporosis are: alendronate, risendronate, ibandronate, and clodronate. 
Pamidronate and zolendronate are utilized in the prophylaxis of bone complications and 
in the hypercalcemia associated to multiple myeloma and to metastatic bone disease 
due to breast and prostatic cancer. All these chemical substances are characterized by 
a high power and selectivity. Nowadays, the literature demonstrates the correlation 
between chronic biphosphonate assumption and onset of osteonecrosis of the jaw.
BRON-J: history and deﬁ  nition
Since Marx’s study other studies on BRON-J have been published. In 2004, Ruggiero 
and colleagues published 63 cases of BRON-J, with the majority of cases being 
dependent on the use of intravenous biphosphonate administration in cancer patients 
and only few patients treated with oral biphosphonates for osteoporosis.2
In 2005, Marx published 119 cases of BRON-J and correlated it to the type of drug 
used, to the invasiveness of the oral treatments, to the dose, and to the assumption Therapeutics and Clinical Risk Management 2009:5 218
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length for a given drug.3 In the same year, Scientiﬁ  c Societies 
published the ﬁ  rst position paper on the topic. The American 
Academy of Oral Medicine described clinical manifestations 
of these lesions, suggested potential clinical ways to prevent 
and to treat the affected patients.4
Several authors later reported extensive revisions of 
myeloma and metastatic cancer disease treated with intrave-
nous biphosphonates, correlating the extension and evolution 
of this complication to the type of drug and to the length of 
treatment.5–7
Intravenous biphosphonates became a standard therapy 
for the control of complications in metastatic bone disease, 
such as pain, local compression, spontaneous fractures, and 
hypercalcemia. In several clinical studies, nitrogen-containing 
molecules (ibandronate, pamidronate, zolendronate) showed 
to be more effective in controlling manifestations of systemic 
malignant bone disease if compared to clodronate, with zole-
dronate being the most potent drug in reducing bone lesions 
extension and in delaying the development of the ﬁ  rst bone 
metastasis.8,9
Despite the high risk of BRON-J development in onco-
logic patients the American Society of Clinical Oncology10 
recommends the use of zoledronic acid even in patients with 
asintomatic metastases or disease in progress.11
In 2006, signiﬁ  cant data emerged from an American 
Association of Oral and Maxillofacial Surgeons position 
paper that reported a consistent incidence of BRON-J, 
depending on prolonged biphosphonate treatment together 
with other related risk factors, such as tooth-alveolar bone 
pathological conditions of inﬂ  ammatory nature.12 This is 
especially true for patients suffering from multiple myeloma, 
and breast or prostatic cancer.
The American Association of Oral and Maxillofacial 
Surgeons also declared a clear disease staging, from not 
visible oral lesions to more severe clinical pictures, such 
as the presence of bone sequestrum and jaw osteolytic 
complications, proposing different therapeutic protocols 
based on the stage of this pathology.12
The American Association of Oral and Maxillofacial 
Surgeons12 established universal criteria for the BRON-J 
tassonomic picture that was valid when three phenotypes 
were present:
1)  Previous or in progress assumption of biphosphonates;
2)  Exposed necrotic bone of the jaws for more than eight weeks;
3)  No history of radiotherapy of the maxillofacial region.
A strict correlation between BRON-J and chronic 
administration of biphosphonates, with incidence ranging 
from 0.8% to 12% is a well recognized phenomenon.13 
Until 2002, however, the incidence was less than a single 
case out of 10,000 treated patients1 and these data refer 
to patients treated with nonaminobiphosphonates, such as 
etidronate or clodronate, at doses used in the therapy of 
osteoporosis. With the introduction of aminobiphosphonates 
(risedronate, zoledronate, ibadronate, and aledronate) more 
powerful in inhibiting bone resorption and in preventing 
osteoporotic fractures, the incidence of this complication 
grew to a relevant proportion of patients, especially in these 
with cancer, with multiple myeloma or metastatic breast, 
prostatic, or kidney cancer.
As suggested by the American Society of Clinical 
Oncology,14 zoledronate and pamidronate show a high potency 
in inhibiting bone and are the chosen therapies in the treatment 
of the malignant disorders of the skeleton. The potency of these 
molecules together with their intravenous administration at 
high dosage in oncologic patients represent the basis for the 
high incidence of BRON-J in these subjects when compared 
to osteoporotic patients treated for the prevention of fragility 
fractures.15 Another potential factor that plays a role in the 
development of BRON-J is the afﬁ  nity for the hydroxyapatite 
crystals by the aminobiphosphonate, with zoledronate showing 
the highest afﬁ  nity versus other molecules of this group.
The American Association of Oral and Maxillofacial 
Surgeons12 pointed out to other potential risk factors for 
BRON-J onset, such as systemic corticosteroid therapy, 
smoke, alcohol, bad oral hygiene conditions, chemotherapy, 
radiotherapy, diabetes, and blood clot diseases. The 
permissive local factors are: oral surgical treatments, ﬂ  ogistic 
lesions, and an excessive pressure of the removable denture 
on a thin mucosa.16
There is no doubt that many factors must occur in BRON-J 
development, such as intravenous prolonged biphosphonate 
administration, and a chronic or an acute periodontitis, both 
responsible for medullary osteomyelitis of the jaw.3
The higher incidence in females than in males could be 
referred to a longer exposure to oral therapy with biphos-
phonates in osteoporosis and to a higher incidence of breast 
cancer17 in women versus men.
From a pathological point of view, BRON-J, such as 
osteomyelitis, begins in the undifferentiated connective 
bone tissue, in the Haversian wall vasa, and in the bone 
marrow spaces. The process progression towards the cortical 
bone and the periostium leads to the concurring presence of 
several anatomopathologic aspects of the lesion: osteolysis 
associated to essudation or to weak growth of granulation 
tissue; osteonecrosis with slow but progressive bordering 
of sequestra; suppurated oral/extra-oral ﬁ  stula caused by Therapeutics and Clinical Risk Management 2009:5 219
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superinfection of necrotic tissue; absence of bone remodel-
ling, hence bone condensation at the border of the seques-
trum; and hypotrophy or atrophy following loss of the bone 
sequestra with low coverage of defect by soft tissues.
According to the American Association of Oral and 
Maxillofacial Surgeons position paper, one can stage 
BRON-J’s patients in two groups: patients treated with 
aminobiphosphonates with no exposed bone segments (patients 
at risk of BRON-J development); and patients presenting 
BRON-J with exposed and necrotic bone segments.
Bone exposure for more than eight weeks can worse the 
clinical picture. In fact, the exposed areas located in the lower 
jaw and having different size (from post-extraction socket 
site to larger areas or multiple areas) remain asymptomatic 
and with no signs of ﬂ  ogosis. The necrotic bone areas 
and exposed bone cause pain due to acute inﬂ  ammation 
of surrounding soft tissues. Mucosa is reddish, swollen, 
bleeding and strongly painful on light pressure. Teeth close 
to the involved bone are often mobile and a local reactive 
limphoadenopathy can be noticed. The clinician can still 
manage this stage of pathology with conservative procedures 
and medical therapy; including antibacterial agents to ﬁ  ght 
infections that involve the exposed and necrotic bone.12
Purulent debris are present in endoral abscessual cavities 
(if the purulent swelling is held by periostium and then by 
perimaxillary muscels) or in extraoral cavities called perioral 
phlegmon (if the osteolytic area is beyond perimaxillary 
muscles insertions). In the ﬁ  rst case purulent material drains 
in the oral cavity. In the second case, purulent material 
drains in preconstituted anatomical spaces delimited by 
connective tissue layers of the neck. Maxillary phlegmon can 
involve canine or buccal spaces. Mandibular phlegmon can 
involve submental, submaxillary, sublingual, submandibular 
spaces. In this case the phlogosis exceeding these anatomical 
limits can spread (for contiguity or through the lymphatic 
system) to the secondary spaces such as pterygomandibular, 
lateropharyngeal, masseteric and pterigo-maxillar spaces.18
The different thickness of the cortexes justiﬁ  es the earlier 
externalization if the pathologic process is located in the upper 
jaw. In the lower jaw the osteolytic damage tend to became 
deeper sometimes reaching the inner edge of the mandibula 
(Figures 1, 2). The involved bone can fracture spontaneously 
because of its reduced elasticity. Furtheremore the purulent 
material can compress nerve endings, causing local 
paresthesia.19,20 This phase, often following the relapse of the 
oncologic disease and/or the antiblastic treatment associated 
to corticosteroid therapy is deﬁ  ned as “complicated phase.”
This phase is characterized by purulent phlogosis, by the 
presence of ﬁ  stulae (Figure 3), by spontaneous fractures, by 
compromized general physical condition with fever, and by 
reactive adenopathy. In this stage conservative treatments 
associated to prolonged antibiotic therapy can be useless 
Figure 1 Osteolytic lesion in the lower jaw of patient treated with Zometa® for 12 months (59 years old, female, breast cancer).Therapeutics and Clinical Risk Management 2009:5 220
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because of the gravity and the extension of the process, with 
a radical surgery being more indicated.
BRON-J diagnosis
BRON-J diagnosis is quite clear if one refers to anamnesis, 
natural history of the oncologic pathology and/or biphosphonates 
administration. The evidence of the clinical lesion is conﬁ  rmed 
with conventional X-rays showing a radiopaque sequestrum 
usually rounded by diffused radiolucency with a blurred con-
tour due to the higher mineralization of the jaw. This aspect, 
due to the ﬁ  xation of calcium in the bone tissue, is responsible 
for the patchy-ragged multilocular appearance of the involved 
Figure 2 Worsening of the lesion after sequestrectomy in patient treated with Zometa® for 12 months (59 years old, female, breast cancer).
Figure 3 Cutaneous ﬁ  stula in patient treated with Aredia® and Zometa® for 24 months (48 years old, female, breast cancer).Therapeutics and Clinical Risk Management 2009:5 221
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area and it assumes a higher deﬁ  nition when a radiolucent 
osteolytic process with a central radiopaque mass of necrotic 
bone is identiﬁ  ed at its periphery.
Computed tomography (CT) can help allow a higher 
deﬁ  nition of the necrotic foci and their relationships with 
the surrounding anatomical structures, making possible to 
quantify the bone sclerosis status. However, CT is not useful 
either in the staging of the asymptomatic patients or in the 
differential diagnosis between a primary tumor (with osteo-
lytic aspect and ill-deﬁ  ned borders) and metastatic spreads 
of prostatic or breast cancer with sclerotic aspect (Figure 4). 
With CT it can be easier to detect mandibular myeloid 
lesions in high vascularized areas with their “mould”, regular 
and well deﬁ  ned characteristics. In these cases the use of a 
contrast medium can help to better identify the lesions.
Once the sequestrum and the periosteal reactive bone 
deposition have been identiﬁ  ed by CT, magnetic resonance 
imaging (MRI) is useful to evaluate the quality of overlying 
soft tissues and the medullary edema, which is a sign of 
ischemia and bone necrosis.
The scintigraphy (Tc99-scan) is the most sensitive 
diagnostic device to identify maxillary edema with vascular 
alterations and to localize bone necrosis even at early stages 
of the disease. Nevertheless this diagnostic technique has a 
limit: Tc99-scan is not able to make a differential diagnosis 
with the metastatic process.21,22
The biopsy of the bone lesions must be carefully evaluated, 
because the procedure itself may damage bone tissue by creating 
a wound which can hardly heal.23
Etiopathogenesis
Nitrogen-containing biphosphonates are used widely for 
the management of metastatic cancer in bone (intravenous 
zoledronic acid or pamidronate), for the prevention and 
treatment of osteoporosis (oral alendronate, risedronate, and 
ibandronate) for the treatment of Paget’s disease of bone 
(intravenous pamidronate and oral aledronate and risedronate), 
and for the short-term management of acute hypercalcemia 
(intravenous zoledronic acid and pamidronate).24,25 The 
nitrogen moiety attached to the side chainof the middle carbon 
of the phosphorus–carbon–phosphorus biphosphonate back-
bone renders these drugs much more potent as inhibitors of 
bone resorption than the bisphosphonates that do not contain 
nitrogen (etidronate and clodronate). Bisphosphonates reduce 
the survival and function of osteoclasts, the bone-resorbing 
cells. These antiresorptive actions largely account for the 
Figure 4 Computed tomographic scan of the bone sequestrum in patient treated with Zometa® for 5 months (75 years old, female, breast cancer).Therapeutics and Clinical Risk Management 2009:5 222
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drugs’efﬁ  cacy in conditions in which the rate of bone resorp-
tion exceeds the rate of bone formation.
Until recently, the only adverse events of substantial 
consequence associated with the nitrogen-containing 
bisphosphonates were upper gastrointestinal intolerance (with 
oral administration) and a short-lived acute phase reaction 
characterized by fever, myalgias, and an inﬂ  uenza-like 
syndrome (with intravenous administration). Now another 
potential complication of these agents–osteonecrosis of the 
jaw–has surfaced.26,27
The Florence experience
Patient’s characteristics
Based on these premises, the aim of the present study was 
the description of clinical and anatomopathological aspects 
of the disease, based on our experience in the management 
of BRON-J.
From February 2004 to September 2006, 19 patients 
(14 females and 5 males) with BRON-J undergoing 
intravenous biphosphonate treatments for cancer were 
examined at the Oral Surgery Department of the Florence 
University Hospital.28,29 The mean age was 66.4 ± 11.7.
In 14 patients the used biphosphonate was zolendronate, 
in one patient pamidronate and in four patients both drugs 
were administrated. The mean interval administration was 
12 months (minimum 5 months, maximum 36 months).
In nine patients (47.4%) the oncologic disease was 
breast cancer, in six patients (31.5%) myeloma, in three 
patients (15.8%) prostatic cancer, and in one patient (5%) 
colon cancer. All the patients were chosen following strict 
diagnostic criteria. The most frequent symptoms were: 
spontaneous pain, swelling, odontogenic abscesses, oral 
ﬁ  stulas, bone exposure due to mucosal ulcer, post-extraction 
alveolitis, and local limphoadenopathy.
The trigger factors were considered to be tooth 
extractions in 10 patients (52.6%), local concussion 
(inadequate removable total denture, edentulous ridges) 
in two (10.5%), root canal treatment in two (10.5%), and 
surgery in three (15.7%). In some cases it was not possible to 
identify a trigger factor. In 10 patients (52.6%) a pre-existing 
inﬂ  ammatory lesions appeared to worsen the development 
of the disease.
The patients were treated with mouth rinses (chlorhexidine 
gluconate 0.12% three times/daily); local or systemic 
antibiotic therapy (amoxicillin 1 g three times/daily; repeated 
local application of methronidazol) and, in case of mycotic 
overinfection, with ﬂ  uconazole 200 mg/daily. Furthermore 
patients underwent hyperbaric treatment.
The treatment of this lesion is extremely difﬁ  cult and 
prolonged. There are no data to support any therapeutic 
choice: surgery often worsens the pathology.
Surgical curettage to achieve mechanical debridement 
are indicated in patients with no complications. More 
invasive surgical treatment (such as deeper courettage, 
sequestrectomies, large resections, and vascularized bone 
grafts) are indicated after clinical changes characterized by 
clinical symptoms (pain, fever), oral or extra oral ﬁ  stula, 
necrotic tissue, pathologic fractures and ineffective antibiotic 
treatment. In our study 13 patients out of 19 were treated 
with curettage and two with major surgery (segmentary 
mandibulectomy). Four patients were not operable.
After one-year follow-up, in most of the cases complete 
healing was not observed, although therapeutic protocol was 
strictly applied. All cases of maxillary location (two out of 
19) reached complete healing thanks to secondary wound 
closure after two months from surgery. On the contrary 
we observed only symptoms of improvement in case of 
mandibular location, probably for the reduced regenerative 
capacity at this site.
In all patients pharmacological biphosphonate treatment 
was suspended. The interruption of biphosphonate 
assumption is one of the most difﬁ  cult decision and should 
be taken in agreement with the oncologist. According to 
Migliorati and colleagues31 the suspension of biphosphonate 
treatment is mandatory, even though there is no immediate 
clinical improvement.
Results and discussion
The treatment of these lesions is extremely difﬁ  cult and 
prolonged. There are no data to prefer any therapeutic choice 
over another, even though surgery appears to worsen the 
disease’s course.
Surgical curettage to achieve mechanical debridement 
is indicated in patients without complications. Chemical 
debridement is carried out with antiseptic irrigations and 
with iodine gauze. Re-infection prevention is improved by 
local ointment use and 0.12% chlorhexidine daily rinses. 
Surgical procedures to achieve a mechanical debridement 
of necrotic tissue, broad spectrum antibiotic treatment for a 
long period, and local antibiotic use are of beneﬁ  t before the 
progression to bone exposure and to small bone sequestra. 
More invasive surgical treatment (such as deeper curettage, 
sequestrectomies, large resections and vascularized bone 
grafts) are indicated in the occurrence of systemic clinical 
symptoms (pain, fever), of oral or extra-oral ﬁ  stulas, of 
necrotic tissue, of pathologic fractures, and of lack of Therapeutics and Clinical Risk Management 2009:5 223
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response to antibiotic treatment. The necrotic tissue curettage, 
sequestrectomy, sliding ﬂ  ap procedure (in two cases with 
oro-antral communication) and peduncle vascularized bone 
graft (in case of fracture) were the surgical treatments used in 
order to stop osteonecrotic lesion progression (Figure 5).
Metastatic foci were not shown by histological examination 
both in the lesion core and in the neighbouring bone tissue. 
Macroscopic healthy bone samples showed cortical necrosis 
with well preserved lamellar bone. Furthermore, empty 
osteocytic lacunae were detected and medullary bone tissue 
appeared necrotic.
All cases of maxillary location reached complete healing. 
In the majority of the cases of extra-maxillary location, 
14 patients (73.6%) complete healing was not achieved, 
although the therapeutic protocols were strictly applied.28,29 
We observed only symptoms of improvement when the 
location was in the lower jaw: ﬁ  ve patients (26.3%), probably 
for the reduced regenerative capacity at this site.
Following the American Association of Oral and 
Maxillofacial Surgery’s staging and treatment criteria,12 
two different clinical courses have been identiﬁ  ed: early 
clinical course, where a small bone sequestrum was identiﬁ  ed 
(Figure 6); and late clinical course, where large neocrotic areas 
worsened by suppurative phlogosis were detected (Figure 7).
The present data showed a higher incidence of BRON-J 
in patients treated with intravenous zolendronate and pami-
dronate. Clinical pictures varied from a more limited 
osteonecrosis areas with or without suppurative phlogosis 
to larger osteonecrotic areas with suppurative phlogosis, jaw 
fractures and extra-oral ﬁ  stulae (Figure 8).
In nine patients (47.3%) we noticed a heavy odontalgia 
following the extraction of teeth located in the maxillary area 
involved by BRON-J. Before teeth extraction, the pain was 
referred to periodontitis involving both the involved teeth and 
the maxillary area close to them. The role of biphosphonates 
in the onset of the lesion was conﬁ  rmed by the time elapsed 
between drug assumption and the lesions’ development 
(about 18 months for zoledronate and about six years for 
pamidronate),30 with reports of lesions initiated even after 
ﬁ  ve months from the beginning of treatment.31,32 All the 
patients of our study underwent a drug treatment longer than 
six months. The length of biphosphonate treatment represents 
a risk factor for BRON-J along with chemotherapy, multiple 
myeloma, renal failure, corticosteroid treatment, anemia, 
hypoproteinemia, infections etc.30,34 Six patients out of 
14 under chemotherapeutic and radiotherapy treatment 
presented larger tissue necrosis refractory to the applied 
therapeutic protocols.
In our study, preferential location of osteonecrotic lesions 
was in the lower jaw: in 14 patients (73.6%) the location was 
in the mandible, in two patients (10.6%) was both mandible 
and maxillary, and in three patients (15.8%) was only maxil-
lary. The location in the mandible seems to be explained by 
terminal vascularization, lower quantity of trabecular bone 
in the lower jaw, and more frequent microinjures due to 
removable denture and masticatory forces.3,20
Figure 5 Spontaneous fracture of the lower jaw in patient treated with Aredia® and Zometa® for 24 months (43 years old, female, breast cancer).Therapeutics and Clinical Risk Management 2009:5 224
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In order to categorize patients with BRON-J, the 
American Association of Oral and Maxillofacial Surgeons 
recognized three stages of the disease.12 In stage 1, the bone 
is exposed but there is no soft tissue inﬂ  ammatory swelling. 
Sometimes there is pain before bone exposure. In stage 2, 
bone is exposed with associated pain and soft tissue infection. 
In stage 3, the patient is affected by the pathologic fractures, 
oral and extra-oral ﬁ  stulae.
According to previous publications.16,35,36 and American 
Association of Oral and Maxillofacial Surgeons’ guidelines, 
we treated patients in Stage 1 (ﬁ  ve patients; 26,3%) and 
Stage 2 (nine patients; 47.4%), with small sequestra, using 
pharmacologic and conservative protocols. In Stage 3 (ﬁ  ve 
patients; 26.3%), when the large suppurative necrotic area 
did not heal, the conservative treatment led to poor results 
so a more invasive surgical treatment should be indicated 
(Table 1).37
Under a therapeutic point of view the clinician should be 
paid attention to the perimaxillary soft tissue study, and to 
their vascularization since a periostium and mucosa highly 
vascularized are the only possibility to try to cover the 
necrotic area after the removal of the sequestrum.
Oxygen therapy with a hyperbaric chamber is useful to 
prepare the patient to the surgical treatment and platelet-rich 
plasma to improve soft tissue attachment (Figure 9).38–42
Conclusions
In conclusion, BRON-J shows a complex clinical picture of 
unclear pathogenesis, even though it seems clearly related 
to intravenous biphosphonate administration. Numerous 
retrospective studies conﬁ  rmed that pharmacologic and sur-
gical therapies are not able to cure this complication, whose 
consequences are extremely invalidating for the patient. 
For this reason, several scientiﬁ  c societies underlined the 
importance of a risk staging for preventing the development 
of the disease in oncologic patients treated with intravenous 
biphosphonates as an adjuvant intervention.4,12,23,24
In the most severe cases the treatment should guarantee: 
pain relief, control of the infection, prevention of the necrotic 
area spreading, and of the development of new contiguous 
lesions. When pharmacologic treatments with antibiotics 
and local antiseptics are not able to control the development 
of BRON-J’s complications, the clinicians should perform 
radical surgical treatments, such as the resection of the 
bone involved followed by reconstructive surgery with 
Figure 7 Advanced lesion of the upper jaw in patient treated with Zometa® for 12 months 
(69 years old, male, multiple myeloma).
Figure 8 Abscessual complication of necrotic bone lesion in patient treated with 
Zometa® for 11 months (61 years old, male, prostatic cancer).
Figure 6 Early clinical picture of the lower jaw in patient treated with Aredia® and 
Zometa® for 24 months (48 years old, female, breast cancer).Therapeutics and Clinical Risk Management 2009:5 225
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vascularized bone grafts.16 Today, prevention is mandatory 
in patients who have to be treated with biphosphonates43 and 
in those that are under treatment for a long period of time.
A multidisciplinary team composed by oncologists, 
pathologists, bone metabolism specialists, dentists, oral sur-
geons, and maxillofacial surgeons must cooperate to carefully 
evaluate the patients’ clinical conditions, general and local 
risk factors, radiological and biohumoral exams, are useful 
in the prevention and in the staging of the disease.
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